Abstract
Context: Glucagon is secreted from pancreatic alpha-cells in response to hypoglycemia and protein intake and acts as a counterregulatory hormone to insulin by stimulating hepatic glucose production, thereby maintaining euglycemia. However, some studies suggest that glucagon regulates insulin availability by stimulating insulin secretion and reducing insulin clearance. Objective: To investigate the glucose-independent effect of glucagon on insulin secretion and insulin clearance in healthy individuals. Methods: A total of 15 healthy participants were included in this single arm, crossover clinical study with two study days. The participants received a four-hour intravenous infusion of glucagon (10 ng × kg(bodyweight)-1×min-1) on the first study day and a four-hour intravenous infusion of glucose (to match the glucose excursions from the glucagon infusion) on the second study day. The primary endpoint was insulin secretion (c-peptide). Results: Overall glucose exposure did not differ significantly between study days (P = 0.0717); however, peak plasma glucose was significantly higher on the glucose clamp day (8.1 (7.5-8.7) vs 7.7 (7.0-8.3) mmol/L, P = 0.0027), reflecting incomplete glucose matching. Steady state concentrations of glucagon were 124 (110-137) pmol/L on the glucagon study day and 3 (2-4) pmol/L on the glucose clamp study day. There was no statistically significant difference in insulin secretion between study days (P = 0.1179), whereas insulin clearance (post hoc analysis) was significantly reduced during glucagon infusion at both hyper- and euglycemia (P = 0.0003). Conclusions: Exogenous glucagon rapidly reduces insulin clearance without a statistically significant effect on insulin secretion, suggesting that glucagon affects hepatic insulin removal in healthy individuals.